AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01287624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine,cisplatin
Description: Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
Study NCT01287624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Paclitaxel
Description: Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Paclitaxel 175 mg/m2, IV, 3h,D1
Study NCT02580019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
Study NCT02215200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (GCSF)
Description: Granulocyte colony stimulating factor (GCSF)
Study NCT06584773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: mTORi added as the fourth maintenance immunosuppressive drug in recipients
Study NCT06584773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard maintenance immunosuppression
Description: standard maintenance immunosuppression: tacrolimus, mycophenolate, prednisone
Study NCT02462746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-Cysteine
Description: The trade name is New Root Herbal Inc.
Study NCT03771378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: After enrollment, all subjects receive TPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
Study NCT03771378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eltrombopag
Description: After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd. blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
Study NCT03953378 — intervention group
Intervention type: OTHER
Intervention: Multi-parametric Flow Cytometry analysis on patients and healthy donors samples
Description: Collection of venous blood (16 mL) and synovial fluid (when available) samples, for each patient, at inclusion and in the frame of the usual medical follow-up at 3 months and between 6 and 12 months, before the onset of MTX (untreated patients) or during the course of MTX treatment (MTX-treated patients).~Collection of anonymous healthy donors blood samples, age- and sex-matched, obtained from the Etablissement Français du Sang.~Multi-parametric Flow Cytometry analysis was performed on these samples to assess CD73 expression on total memory T cells and within T helper lymphocyte subsets, their cytokine production and AMPase functions. For FoxP3 intracellular staining, cells were treated using the FoxP3 Fixation and Permeabilization kit (Life Technologies), according to manufacturer instructions. Stainings were analyzed on a LSR-Fortessa™ (BD Biosciences) with conserved settings throughout the entire study and data were analyzed using FlowJo™ Software (Tree Star v10.4).
Study NCT01370564 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diuretics
Description: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Study NCT03787394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adding taste enhancer
Description: Comparing sensory profiles of food products either enriched with FAAA-conjugates or plain
Study NCT03787394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: adding taste enhancer
Description: Comparing sensory profiles of food products either enriched with FAAA-conjugates or plain
Study NCT01738048 — intervention group
Intervention type: PROCEDURE
Intervention: Reconstruction
Description: Reconstructive surgery after mastectomy, either by expander or autologous tissue. Includes both primary and secondary reconstruction
Study NCT02907021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard-of-care treatments for LV impairment
Description: Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
Study NCT01605617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fesoterodine fumarate
Description: PTNS + 4mg of fesoterodine fumarate for 12 weeks
Study NCT03711799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to services via peer coaching
Description: This intervention will allow for half of the participants, randomly selected, to get help navigating the system of acquiring services for their child. These participants will be assisted by a coach who are also parents of a child with autism and have already been through the process.
Study NCT02215200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for ATG)
Description: Normal saline administered by IV infusion to mimic ATG
Study NCT02215200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for GCSF)
Description: Placebo prepared to mimic 6mg subcutaneous injection of GCSF
Study NCT02215200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for GCSF)
Description: Placebo prepared to mimic 6mg subcutaneous injection of GCSF
Study NCT01605617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fesoterodine fumarate
Description: PTNS + 4mg of fesoterodine fumarate for 12 weeks
Study NCT01605617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: PTNS + placebo for 12 weeks
Study NCT01605617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PTNS + placebo for 12 weeks
Study NCT01605617 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Tibial Nerve Stimulation (PTNS)
Description: PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
Study NCT01605617 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous Tibial Nerve Stimulation (PTNS)
Description: PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
Study NCT04272281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: medical shared decision
Description: The experimental group will use the share decision making tool during consultation to adapt antibiotherapy
Study NCT04272281 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: control group will act as usual in their practice.
Study NCT02935335 — intervention group
Intervention type: DRUG
Intervention: Menotrophin
Study NCT02576067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose methotrexate
Description: Study participants will additionally receive 1 mg daily oral folate.
Study NCT02576067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01512862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
Study NCT01512862 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Placebo
Description: Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
Study NCT04700293 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AYMES AMSTERDAM
Description: AYMES AMSTERDAM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
Study NCT00868439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patiromer
Description: Active investigational drug
Study NCT00868439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02352558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: Patients will receive BBI608 orally twice daily, with doses separated by approximately 12 hours. The starting dose for all cohorts will be 240 mg twice daily. Subsequently, cohorts at alternate dose-levels (480 mg twice daily) may be enrolled as determined by the criteria for dose-escalation.
Study NCT02691949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: mycophenolate mofetil 1# BID-2# BID
Study NCT02352558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be taken orally at a dose level of 40 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Patients over the age of 75 years are allowed to begin dexamethasone at a dose of 20 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Dexamethasone should be taken with food or milk, and a minimum of 2 hours should separate a dose of dexamethasone from a dose of BBI608.
Study NCT00016978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Study NCT00016978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00016978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00016978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT01142154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prodarsan
Description: Prodarsan TID, oral solution, 6-8 days
Study NCT02465775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape treatment
Description: Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
Study NCT00598858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT00598858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT00117650 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad2/HIF-1α/VP16
Description: a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections
Study NCT00117650 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad2/HIF-1α/VP16
Description: one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
Study NCT00117650 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad2/HIF-1α/VP16
Description: a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
Study NCT00117650 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo Control)
Description: a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
Study NCT02181400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ellex Integre NIR laser
Description: Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period.
Study NCT03928171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-abdominal pressure during laparoscopy
Description: Insufflation pressure of the abdomen during laparoscopy
Study NCT04299581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: a PD-1 immune check inhibitor
Study NCT04299581 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: US/CT-guided Percutaneous Cryoablation
Description: Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
Study NCT03071900 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: circulating tumor cell analysis
Description: Detect circulating tumor cells with CellCollector in SCCHN and control group.
Study NCT03168009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: Patients will undergo bariatric surgery as routinely scheduled. The type of bariatric procedure will be suggested by the surgeon based on clinical considerations.
Study NCT01299441 — intervention group
Intervention type: DEVICE
Intervention: ECOM ETT
Description: Intubation with ECOM endotracheal tube (ETT)
Study NCT00579475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifegyne
Description: tablets, 50 mg every other day
Study NCT00579475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02468882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Watercress
Description: 100g of watercress daily during radiation therapy
Study NCT00587899 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pulmonary Vein Isolation
Description: The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation using a device that delivers radiofrequency energy to the heart muscle in order to create scar tissue to block electrical impulses that can trigger episodes of AF.
Study NCT04117334 — intervention group
Intervention type: OTHER
Intervention: Bracing
Study NCT04357587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenously (IV) on days 1, 22, and 43
Study NCT04357587 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation
Description: Daily fractions of 200 cGy, 5 days a week for the first 5 weeks of the study, excluding weekends
Study NCT04357587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2 orally twice a day on days where radiation therapy is given
Study NCT02135588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)
Study NCT02599376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LiDCOrapid
Description: Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
Study NCT02599376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiDCOrapid
Description: Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
Study NCT04486742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Itch CBT
Description: Telemedicine CBT sessions with a therapist to address atopic dermatitis related concerns.
Study NCT00365183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motexafin gadolinium and pemetrexed
Description: 1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
Study NCT03662854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hair Stimulating Complex (HSC)
Description: Patients will receive 2 mL of HSC separated by 6 weeks (total of 4 mL of HSC)
Study NCT02352558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered at 1.3 mg/m2/dose as a 3-5 second bolus intravenous (IV) injection or subcutaneous injection twice weekly for 2 weeks (Day 1, 4, 8, and 11) followed by a 10-day rest period (Day 12-21).
Study NCT02352558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib will be taken orally once daily with a meal and a large glass of water. For patients having difficulty swallowing, imatinib can be dissolved in water or apple juice for intake. The dose of imatinib is 400 mg for CML patients in the chronic phase and 600 mg for CML patients in the accelerated phase or in blast crisis. A minimum of 2 hours should separate a dose of imatinib from a dose of BBI608.
Study NCT02352558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be taken orally once daily with water. Do not open, break, or chew the capsules. The dose of ibrutinib is 420 mg for patients with normal liver function and is 140 mg for patients with mild liver impairment (Child-Pugh class A). A minimum of 2 hours should separate a dose of ibrutinib from a dose of BBI608.
Study NCT02322671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Montelukast
Description: It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.
Study NCT02322671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 1 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
Study NCT02724657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buteyko Method
Description: Intervention will be held twice a week during 3 weeks.
Study NCT02322671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 2 Montelukast
Description: It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
Study NCT02995772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitors (Arimidex)
Description: Comparison of efficacy with chemotherapy
Study NCT01434160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skyla (Levonorgestrel, BAY86-5028)
Description: Levonorgestrel intrauterine contraceptive system (LCS12) insertion into the uterus at insertion visit 2 with the study treatment of 12 months. An optional follow up phase up to 3 years will be offered for all subjects completing 12 month treatment time.
Study NCT03318861 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KITE-585
Description: A single infusion of KITE-585 autologous anti-BCMA CAR T cells
Study NCT03318861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study NCT03318861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study NCT02995772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Comparison of efficacy with chemotherapy
Study NCT02995772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOB
Description: Comparison of efficacy with chemotherapy
Study NCT02995772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FAC
Description: Comparison of efficacy with hormonal therapy
Study NCT02995772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitors (Femara)
Description: Comparison of efficacy with chemotherapy
Study NCT02995772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitors (Aromasin)
Description: Comparison of efficacy with chemotherapy
Study NCT02112383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior group therapy
Description: For participants in the group intervention condition, the modules from a self-help treatment for procrastination will be delivered at four consecutive three-hour sessions at the Student Health Centre at Karolinska Institutet, with approximately two modules given at each session. The sessions will be spaced two weeks apart, during which participants are instructed to complete assignments related to the modules that were in focus of the previous session, e.g., goal-setting, time management, and behavioral experiments, which they are advised to present and discuss with the other participants.
Study NCT02112383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy
Description: For participants in the Internet-based condition, the modules from a self-help treatment for procrastination will be distributed weekly during the treatment period, with one module given each week, i.e., ten weeks. In comparison to the group condition, participants will not receive a therapist contact or attend any sessions. In addition, the participants are expected to complete both the reading material and the assignments that are included in each module.
Study NCT03911128 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational study - no intervention
Study NCT04694274 — intervention group
Intervention type: DEVICE
Intervention: stabilization splint
Description: The device made of a hard acrylic on stone cast of the upper jaw in the centric relation position. It has a thickness of 1.5 mm at the level of the first molar.